Hikal Ltd
Hikal Ltd Company History
Hikal is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities.
2002
Appoints Mr Bimal Kishore Raizada as the Additional Director of the company.
2002
2003
Board approves for the issue of Bonus shares.
Signs agreement with US based pharmaceutical company to supply Gabapentin, a $2 billion anti-depressant that is going off patent.
Enters into Long term supply agreement with a leading Corp protection company in USA for supply of new generation agrochemical.
2003
2004
Hikal Limited has informed that the Company had applied for delisting of its securities from Ahmedabad Stock Exchange and Pune Stock Exchange. Pune Stock Exchange Ltd. has informed the exchange that it has approved company's request and the equity shares of Hikal Ltd. are delisted from Pune Stock Exchange Ltd. wef January 16, 2004.
Hikal enters into long term agreement with Bayer CropScience AG
Hikal acquires European Pharma Distributor Marsing & Co.
Hikal takes over Danish co
2004
2005
Hikal Ltd has entered into a long term agreement with a leading American Company, Crompton Corporation, USA, for manufacture & supply of a New Generation crop protection product.
Hikal joins Pfizer's epilepsy drug marketing row in US.
2005
2006
Hikal Ltd, manufacturer of pharmaceutical and agrochemical ingredients and intermediates, has signed an agreement with Germany's third-largest chemical company Degussa for supplying pharmaceutical intermediates and active pharma ingredients (APIs).
The Registered Office of the Company has been shifted from 6, Nawab Building , 327, Dr. D. N. Road, Fort, Mumbai-400 001 to 717/718 Maker Chamber V, 7th Floor, Nairman Point, Mumbai-400 021.
2006
2011
The Board has appointed Dr. Wolfgang Welter as an Additional Director.
The prestigious Hikal Cup Corporate Tennis Tournament for the year 2011 was played at the Bombay Gymkhana Tennis Courts.
2011
2012
Hikal Board recommends Final Dividend on the Equity Share Capital @ (60%) Rs. 6/- (Rupees six only) per Equity Share, nominal value of Rs. 10/- each
2012
2013
HikalÂs Pharmaceutical Manufacturing Site in Gujarat, India received US FDA Approval.
Hikal Ltd Board recommends Dividend on Equity Share Capital @ 25% [Rs. 2.50 per equity share, (nominal value of Rs. 10 each)] for financial year 2012-13
Hikal signs a long term supply agreement with a leading global Biopharmaceutical Company
2013
2014
Hikal Ltd Board recommends Dividend on Equity Share Capital [Rs. 4.5/- per equity share, (nominal value of Rs. 10/- each) [including interim dividend of 20% (Rs. 2/- per equity share) declared / paid
Hikal Completed successful EDQM Audit of its Bangalore facility
2014
2015
Hikal has splits its face value from Rs. 10 to Rs. 2
2015
2017
Hikal won the most coveted ICC Award for Excellence in Human Resource Management in the Chemical Industry for the year 2016.
2017
2018
The Global Employer Branding Institute and World HRD Congress has conferred Hikal with the ÂNational Best Employer Brands 2018Â.
The Company has issued Bonus Shares in the Ratio of 1:2.
2018
2019
Hikal was conferred with the CSR Leadership Award for Best Corporate Social Responsibility Practices by the World CSR Congress.
Hikal won the coveted Confederation of Indian Industry (CII)Âs 'Significant Achievement in HR Excellence' award at the CII National HR Excellence Award.
2019
2021
"Hikal signs 10 year multi product contract with a leading global pharmaceutical innovator Company".
2021
